beta-amyloid protein


Also found in: Medical.

be·ta-am·y·loid protein

 (bā′tə-ăm′ə-loid′, bē′-)
n.
An amyloid that circulates in human blood and in cerebrospinal fluid and is deposited into plaques found in the brains of patients with Alzheimer's disease. Also called amyloid beta-protein.

[From the beta sheets characterizing its structure.]
Mentioned in ?
References in periodicals archive ?
APP breaks up to form the famous beta-amyloid protein and the much less famous AICD protein.
Aducanumab, an antibody, clears away sticky beta-amyloid protein deposits in the brain that are linked to dementia.
Two potential sources of chronic stress are the accumulation of clumps of beta-amyloid protein in the brain, a known hallmark of Alzheimer's, and diseased arteries which are also linked to dementia.
SAN DIEGO, Calif, January 8, 2016 -- Investigators here have discovered that high sugar caused by Type 2 (adult-onset) diabetes and the beta-amyloid protein associated with Alzheimer's disease induce the same pathological modification on multiple enzymes in the brain.
Signs of the beta-amyloid protein were found in the brains of seven patients aged 36 to 51 who had died from Creutzfeldt-Jakob Disease (CJD) after receiving growth hormone from the pituitary glands of dead people.
Researcher Abha Chauhan, PhD, and associates say an extract in the nuts may provide a protective effect against oxidative damage caused by beta-amyloid protein.
Beta-amyloid protein is the primary material found in the sticky brain "plaques" characteristic of Alzheimer's disease.
In both studies, scientists looked for signs of beta-amyloid protein, which forms clumps in the brains of Alzheimer's patients and is a key hallmark of the disease.
In Alzheimer's, the gene is assumed to affect the metabolism of the beta-amyloid protein, slowing clearance and causing it to clump onto neurons.
Professor Martins is credited, in collaboration with Australian and German scientists, with isolating beta-amyloid protein, which forms amyloid plaque deposits in the brain, a characteristic diagnostic feature of Alzheimer's disease.
Exebryl-1 has been shown to inhibit beta-amyloid protein aggregate formation in brain, as well as disaggregate amyloid plaques that are already present.
It decreases the amount of plaque-forming beta-amyloid protein by changing the point at which gamma secretase cleaves the amyloid precursor protein.